Background

Square Pharmaceuticals Ltd. (SPL), the pharmaceutical giant in the country, is a trusted name

in the industry of manufacturing quality medicines for more than four decade.

SQUARE today symbolizes a name – a state of mind. From the inception in 1958, it has today

burgeoned into one of the top line conglomerates in Bangladesh.

SQUARE Pharmaceuticals Ltd., the flagship company, is holding the strong leadership

position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to

becoming a high performance global player.SPL was

FIRST to manufacture and market Metronidazole, Ampicillin and Cotrimoxazole after the

expiry of patents.

FIRST to export antibiotics and other ethical drugs overseas.

FIRST to develop sustained release technology locally.

FIRST to achieve an all time industry high record sales turnover of US$ 25 million.

FIRST to locally produce high tech Metered dose Inhalation (MDI) formulations.

FIRST to locally produce diclofenac sodium in the chemical division.

In addition to these FIRSTs, SQUARE Pharmaceuticals Limited (SPL) was always ahead in

introducing new products in the market.

1.1    Profile of Square Pharmaceuticals Ltd.Corporate Headquarters    :               SQUARE CENTRE

48, Mohakhali Commercial Area

Dhaka 1212, Bangladesh

Factory                                  :               Shalgaria, PabnaTown, Pabna

Established                           :               1958

Constitution                          :               Public Limited Company

Chairman                              :               Mr. Samson H. Chowdhury

Managing Director              :               Mr. Tapan Chowdhury

Details of Business             :               Pharmaceutical Products/ Bulk Chemicals/ AgroVet

Products

Authorized Capital         :           Tk. 1000 million

Paid-up Capital                    :               Tk. 496.8 million

No. of Employees                :               2703

ProductRange                     :               Pharma                  – 91 products in 185 dosage forms

Chemical Division               – 7 products

AgroVet Division  – 7 products

Name of the Banker            :               Janata Bank, 1, Dilkusha, Dhaka

CitiBank N.A., 122-124, Motijheel, Dhaka

Standard Chartered Bank, 18-20, Motijheel, Dhaka

Credit Agricole Indosuez, 47, Motijheel, Dhaka

Bank Asia Ltd., 113-116,Tejgaon, Dhaka

Manufacturing Units            :               1. Pharmaceutical Division

2. AgroVet Division

3. Chemical Division

Square Pharmaceuticals Ltd. (SPL), the pharmaceutical giant in the country, is a trusted name

in the industry of manufacturing quality medicines for more than four decade.

With a capital of Tk. 55,000, a floor space of 3000 sft, and a team of 12 persons, SPL made

its humble debut as a partnership firm in 1958.

Within a span of only six years, under the farsighted vision of the management, and the

dedicated efforts of the company, its turnover reached the mark of Taka one million. With the

growth of turnover came the increase in number of employees, which in 1964stood to 50. At

this point of time the partnership firm was transformed into Private Limited Company. In 1964,

PL’s Authorized Capital was Tk. 5,00,000 and the Paid up Capital was 4,00,000.

During the mid-seventies (1975) SPL entered into a technical collaboration agreement with

Janssen Pharmaceuticals, Belgium, which is a subsidiary of Johnson and Johnson

International, USA. Since its inception SPL practices Good Manufacturing Practices (GMP),

as recommended by the World Health Organization (WHO).

Another technical collaboration came under way, this time with F Hoffmann-La Roche Ltd.,

Switzerland, in 1982. But the fruits of this agreement could not be reaped on the account of

the Drug Ordinance of 1982. Nevertheless, SPL’s growth was not being stunted. In 1982,

turnover reached over Tk. 240 million, and the payroll increased 400 heads, and by 1988

SPL’s turnover exceeded half a billion taka., and the number of employees to 750.

A new factory built in 1987, with all the modern machinery, extensive development of the

domestic market, and infiltration into foreign ones like UK and Singapore. Led to this

phenomenal growth SPL is the first company in the country ever to export pharmaceuticals

finished goods abroad. At present SPL is exporting its products to Nepal, Myanmar, Pakistan,

Sri-Lanka, Combodia, and Russia.

With its finished goods already dominating markets at home and abroad, SPL started

production of pharmaceutical raw materials groom its new unit, christened as Square

Chemical Division, in 1995. The items in production under this unit are Diclofennac Sodium,

Amoxycillin, Cloxacillin and Paracetamol.

To sustain the changing environment SPL made convert itself into Public Limited Company in

1991. With a brilliant track record SPL became the first company in Bangladesh to cross the

Billion Taka mark turnover in 1992. In 1994 SPL got its share listed in the Dhaka and

Chittagong Stock Exchanges. Authorized Capital towered to billion taka and paid up capital by

now is taka 250 million. Presently Square is family of 1321 members.

In 1996 an agreement was signed with M/s Tanvec, UK for the establishment of the second

formulation unit (Pharma II) at Kaliakoir, Gazipur. This factory, which built with a view to get

the approval of USFDA/MCA, is completed in the year 2000, and without doubt, help SPL

continue to command its leadership through the next millennium as well.

1.2    Chronology since inceptionYear                                             Events                                                                  

1958 :Debut of Square Pharma as a Partnership Firm.

1964 :Converted into a Private Limited Company.

1974 :Technical Collaboration with Janssen Pharmaceutica, Belgium, a subsidiary of Johnson and Johnson  International, USA.

1982 :Licensing Agreement signed with F. Hoffmann-La Roche Ltd., Switzerland.

1985 :Achieved first position in the Pharmaceutical Market of Bangladesh among all national and multinational companies.

1987 :Pioneer in pharmaceutical export from Bangladesh.

1991 :Converted in to a Public Limited Company

1994 :Initial Public Offering of Square Pharmaceutical Shares.

1995 :Chemical Division of Square Pharmaceuticals Ltd. starts production of pharmaceutical bulk products (API).

1997 :Won the National Export trophy for exporting pharmaceuticals.

1998 :Agro-chemicals & Veterinary Products Division of Square Pharma starts its operation.

2001 :US FDA/UK MCA standard new Pharmaceutical factory goes into operation built under the supervision of Bovis Lend Lease, UK.

2004 :Signing of agreement with ROVIPHARM, Vietnam to manufacture and market SQUARE products under license in Vietnam.

 Secured the top position for the best published accounts and report for 2003 in the manufacturing category for transparency and excellence in corporate reporting.

2005New State-of- the-Art Square Cephlosporins Ltd. goes into operation; built under the supervision of TELSTAR S.A. of Spain as per US FDA/ UK MHRA requirements.

1.3    Global Operations of SPLSQUARE has extended its range of services towards the highway of global market. It

pioneered exports of medicines from Bangladesh in 1987. Through its extended marketing

operations, SQUARE is now selling its finished goods in many countries of Asia and Europe

including:

Cambodia

Myanmar

Nepal

Pakistan

o ØRussia

o ØSri Lanka

o ØUkraine

o ØYemen

In addition, registration of many of SQUARE’s finished goods in other countries of Asia, Europe,

and Africa is now under process.

1.3.1     Partnership and agreement with different world players

1974       : Technical Collaboration with Janssen Pharmaceutical, Belgium, a subsidiary of

Johnson &             Johnson International, USA

1982       : Agreement signed with F. Hoffmann-La Roche Ltd., Switzerland

1999          : Agreement with Bayer AG, Germany

1999          : Agreement with Eisai Co. Ltd., Japan

1999          : Technical know-how transfer to foreign pharmaceutical company

2000       :  Establishment of Square Spinnings Limited.

2001       :  Operation of new factory with a view to get USFDA/MCA approval and production

support for      expanding export operations.

2002       :  Establishment of Square – Fashions Limited and Square – Knit fabrics Limited.

2003       :  Turnover crosses Four Billion Taka mark.

Overview of Square Pharmaceuticals Ltd.

Chapter

2

 

2.1                Manufacturing Facilities 

SQUARE is committed to ensure strict compliance with CGMP norms and regulatory

requirements in every phase of manufacturing, quality assurance, and distribution of medicines.

To comply with CGMP SQUARE has state-of-the-art technology in production and quality control.

In addition, USFDA/MCA standard new plant is now at the completion stage.

 

Documented Quality Management System (QMS) is integral part of all of SPL operations.

People at all levels are committed to adopt advanced technology for continuous development.

Being confident with the sophisticated manufacturing and quality assurance technology of

SQUARE, multinationals from industrialized countries now have agreements with Square for

having their products manufactured in Bangladesh.

2.2            Product MixSQUARE has latest technologies for production of a wide varieties of dosage forms including

Tablet, Sustained Release formulation, Capsule, Metered Dose Inhaler (MDI), Injectable, Syrup

(liquid and dry), Suspension (liquid and dry), Pediatric Drops, Nasal & Ophthalmic formulations,

Topical Gel/Ointment/Cream, and oral care formulations.

Current product mix of Square Pharmaceuticals Ltd. comprised of products from the following

types of Drug Delivery Systems:

Tablets

o Non-coated (Vaginal, Dispersible, Chewable, Plain)

o Coated (Sugar coated, Film coated, Enteric coated)

o Sustained released (coated/non-coated)

o Capsules

o Injectables

Vials containing dry powder for injections

Small volume parenterals

Liquids

Oral (suspension, syrup, drops, and stomatologicals)

Topical solutions

Nasal drops

Dry powders

Oral (for reconstitution to make suspension, syrup and drops)

Topical

Semisolids (creams, ointments and gels)

Solid suppository formulations

Metered Dose Inhalers (MDIs)

Dry Powder Inhalers (DPIs)

Sterile Ophthalmic Formulations (drops)

Therapeutic Range (Formulation)

Analgesics/AntipyreticsAnthelmintics

Antiallergics

AntiviralsBone resorption preparations

Dermatologicals

Antidepressants

Antidiabetics

Antidiarrheals

Antiemetics/Gastroprokinetics

Antifungal Systemic

Antigout

Antihistaminics

Antihypertensive / Antianginal

Antiinfectives/Antibacterial

Antimalarial

Antiprotozoals

Antiseptics/Disinfectants

Antispasmodics

Antiulcerants

Enzymes

Expectorants/Antitussives

Hematinics

Lipid modifiers/Antiobesity

Nootropics

NSAIDs

Ophthalmic preparations

Sedatives/Tranquilizers/Muscle Relaxants

Bronchodilators/Antiasthmatic

Vitamin and mineral preparations

Androgen suppressants

Anti-migraine

Laxatives

Neurological

2.3    QualitySQUARE is committed to ensure better life through quality medicine. SPL has defined its Quality

Policy to fulfill this commitment. To achieve and maintain a steady quality, a range of

sophisticated state-of-the-art technology is engaged in operation. SQUARE has adopted the

latest quality philosophy by organizing a well-equipped Quality Assurance Department in the

plant in addition to Quality Control Department. Above all highly qualified, well-trained,

experienced and dedicated professionals are most valuable assets of Square Pharmaceuticals

Ltd.

2.4    Research and DevelopmentSPL’s Research and Development is devoted to improve the health care facility of people.

Square Pharmaceuticals Ltd. has brought in advanced technology for its Research and

Development works. Research & Development includes the bibliographic search aided by a

resourceful library, design and selection of process that maximizes efficiency and minimizes the

environmental impact, accelerated and long term stability testing, product quality optimization and

translation of new scientific insights into the products. R&D Department is also devoted to

extensive research and development work in synthesizing bulk chemicals for Chemicals Division.

Having started as an importer of technology, R&D Dept. from 1999 has started to export

technology to SQUARE’s global customers. To support Research and Development work latest

Information Technology (IT) is available with us and SQUARE is now fully prepared to meet the

challenge of twenty-first century.

2.5    Chemicals Division for Bulk Drug ManufacturingIn 1995, SQUARE has established a separate division for the manufacturing of bulk drugs.

Currently this division is producing the following bulk chemicals for the domestic pharmaceutical

companies:

Paracetamol BP/USP

Diclofenac sodium BP

Diclofenac free acid INN

Diclofenac diethylamine

Diclofenac potassium INN

Flucloxacillin sodium BP

Amoxicillin trihydrate BP/USP (compacted and micronized)

Cloxacillin sodium BP/USP (compacted and micronized)

Ampicillin trihydrate BP/USP (compacted and micronized)

Cephalexin monohydrate BP/USP (compacted and micronized)

2.6    Distribution NetworkSQUARE is committed to ensure better life through quality medicine. The ultimate motto is to

ensure customer satisfaction by exceeding their level of expectations. SPL has 14 Sales and

Distribution offices in the following places in Bangladesh:

 

Depot Address Phone

Dhaka 355-356, Tejgaon Industrial Area, Dhaka-1208.(880-2)

8828775

Pabna Hospital Road, Salgaria, Pabna.(880-731)

66580

Bogra 877/A, MS Road, Bakshi Bazar, Malati Nagar, Bogra(880-051)

64747

Rangpur House # 36, Road # 2, R K Road, Islambag , Rangpur. (880-0521)

63588

Khulna Alhamdulillah, 25 Usufe Road, Mirzapur, Khulna-9100 (880-041)

732330,

724654

Barisal 502/532 South Alekanda, 1 No. C & B Pool, C & B Road, Barisal. (880-0531)

53661, 56778

Comilla 400/363, Shishu Mangol Road, Kandirper Comilla.(880-081)

72320

Mymensingh 5/A/04 & 5/A/05, Shaheb Quarter, Kachijuli, Mymensingh (880-091)

55143

Chittagong House No-1/C, Baijid Bostami Road, East Nasirabad, Chittagong-4000. (880-031)

654423

Maizdee 234/B, Hospital Road, Maizdee Court, Noakhali.(880-0321)

61683

Sylhet Sabina Mohal, 44, Payra, Darshandewry, Dorga Mohalla, Sylhet. (880-0821)

725298

Tangail Biswas Betka, Dhaka Road, Tangail (880-0921) 53488

Rajshahi 106, Ambagan, Senanibas Sarak, Rajshahi (880-0721) 760877

Faridpur Mission Road, Christian Mission, Police Line, Faridpur

(880- 0631) 63561

The extensive marketing network comprising of latest technical and logistic support along with

887 skilled and qualified field staffs is a key to succeed in achieving customer satisfaction level

beyond their expectation. The modern warehousing and completely computerized invoicing

facilities of SQUARE ensures just-in-time delivery and high customers’ satisfaction.

Resources

Total Distribution personnel :887

Permanent : 420

Casual : 467

 

Central Depot :01

 

Depot :14

 

Vehicles :212

 

2.7    New Plant of SPLSQUARE is now on it’s way to becoming a high performance global company. To this end

SQUARE has built a new plant that went into operations by the end of 2001. This plant is the first

of its kind in Bangladesh with its MCA of UK and USFDA standard manufacturing and quality

assurance facilities.

The implementation of Pharma Unit at Dhaka (Kaliakoir) is carried out under the supervision of

M/s. Tanvec Ltd. of UK. In view of the complex and complicated design and high quality standard

required for USFDA/EU/MCA specifications the progress of implementation has to be slower. It

may be noted that during the year under review total investment increased by Tk. 463,667,368

from Tk. 317,321,566 as on 31-03-98 to 780,988,934 as on 31-03-99 on various heads as shown

below:

Square Dhaka Unit Project work was started from October 1996. After technical review and in the

best interest of the project in order to achieve quality work as State-of-the-art facility to meet the

requirement of the USFDA/MCA Good Manufacturing Practice the original project completion

schedule had to be extended.

The Dhaka Unit New Pharmaceuticals Production Facility at Kaliakoir is one of its kind in the

country to face the challenge of free world market in the beginning of new millennium.

The State-of-Art Facility incorporated certain basic requirement in the area of Purified Water

System. Floor Construction, HVAC System Process Equipment and Validation/ Qualification

Documentation as stipulated by USA, EU and other developed countries.

2.8    Export marketIn an effort to expand the market for the pharmaceutical products beyond the border, the

company has been successful in exporting to several countries at an increasing ratio of its

turnover as indicated below:

Taka in ‘000)

Year Turnover (Gross) Exports % age of GT

2001-2002 2,422,785 44,361 1.83%

2000-2001 2,055,418 15,082 0.73%

1999-2000 1,827,983 11,503 0.63%

1998-1999 1,595,590 163 0.01%

The company has so far been able to enter into the markets of Russia, Pakistan, Sri Lanka,

Myanmar, Nepal, and Cambodia. It is expected that after the Dhaka Unit goes into production the

company will succeed in entering the markets of developed countries with expanded share of

exports.

2.9    Corporate Financial HighlightsHead                                                                                       Amount                                                                                

Authorized Capital                                                                Tk. 1000 Million

Issued, Subscribed and Paid-up Capital                          Tk. 496.8 Million

Reserve/Surplus (Retained Earnings)                              Tk. 872 Million

Share Premium                                                                     Tk. 800 Million

Long Term Loan                                                                   Tk. 210 Million

2.10Marketing Performance2.10.1       Product

Square’s product is viewed among the most quality products in the country. This quality image

has increased its credibility among the doctors. It is also pioneer in introducing many new

products sought by the doctors. Introducing new products is one of the important objectives of the

company. But there are some complaints regarding packaging of the products. But the company

has now concentrated in this area and working hard to bring attractive and good packaging

2.10.2       Pricing

Government fixes Price of most of the essential drugs. The number is 118 products. The

company can fix price of other products but needs to take approval of government. In pricing a

product, Square Pharmaceuticals Ltd. usually follows target pricing. Premium prices cannot be

charged, as all the competitor products are similar and not much distinguishable from each other.

But prices of some products are still higher than the competitors. But since Square

Pharmaceuticals Ltd. does not compromise with the quality, sometimes they have to charge

higher to ensure the highest quality possible.

2.10.3       Promotion

Personal selling is the main weapon in pharmaceutical industry. Medical representatives of the

company go to the doctors to promote the products. The quality of medical reps is assumed to be

the best in Square Pharmaceuticals Ltd. They are selected after a careful scrutiny and are sent to

market after some extensive training. This helps Square Pharmaceuticals Ltd. to maintain the

quality of its medical reps. Advertising can be given only in magazines related to health

profession. Square also utilizes every opportunity to explore this area

2.10.4       Distribution

Square distributes its products all over the country using its own distribution channel. It has a

large number of vehicles and sales depots to ensure coverage of the whole country. Its coverage

is the best in the country.

SQUARE’s NATIONWIDE DISTRIBUTION

Corporate Profile of SQUARE

Chapter

3

 

Although Square started its operation in pharmaceutical sector and leader in the field, it is today a

synonym of quality toiletries, health products, textile products and AgroVet products. It has also

expanded its business in real estate, engineering construction, hospitals, electronic media and

other trade & services. SQUARE is now one of the fastest growing and fastest diversifying

conglomerate in Bangladesh.

 

3.1                Square FamilySquare family is currently comprised of following companies:

Square Pharmaceuticals Ltd.

Square Textiles Ltd.

Square Spinnings Ltd.

Square Toiletries Ltd.

Square Consumer Products Ltd.

Square Informatix Ltd.

Square Health Products Ltd.

Square Agro Ltd.

Mediacom Ltd.

 

3.2                Associated CompaniesAs part of vast diversification, SQUARE has the following associated companies:

Sheltech

Pioneer Insurance Company Ltd.

Mutual Trust Bank Ltd.

National Housing Finance And Investment Ltd.

Aegis Services Ltd.

Maasranga Productions

3.3                Corporate Headquarters:Corporate Headquarters of SQUARE is now located at the following address:

SQUARE CENTRE’

48, Mohakhali Commercial Area, Dhaka-1212, Bangladesh

Tel. : (880)-2-8827729 (10 lines); Fax : (880)-2-8828608, 8828609

Email: square@bangla.net, Web: http://www.square-bd.com

3.4                Board of Directors

Mr. Samson H. Chowdhury Chairman

Mr. Tapan Chowdhury Managing Director

Dr. Kazi Harunar Rashid Director

Mr. Samuel S. Chowdhury Director

Mr. Anjan Chowdhury Director

Mr. Kazi Iqbal Harun Director

Mrs. Jahanara Chowdhury Director

3.5                Human resourcesIn its efforts for human resources development in all spheres of its activities the company offered

various courses of training. The company conducted in-house courses of different duration for

upgrading skill of 395 employees during the financial year of 1998-1999. 22 employees were sent

to various local institutes for training on different topics, 7 employees were sent abroad for

training/attending seminars/symposiums on various subjects including general management, 3

expatriates were also invited for holding various discussion forums for officers/staff of the

company.

The Breakdown of HRJob Location Manager and

above

Executive Non Executive Total

Corporate

Headquarters

46 123 123 292

Chemicals Division 2 12 64 78

Pabna Plant 19 59 459 537

Dhaka Unit 14 61 168 243

Distribution 3 17 174 194

Field Force(SPL) 942

Field Force(Agrovet) 70

Field Force(Pesticide) 25

Total HR 84 272 988 2381

 

The Supervision Ratio

Criteria Manager  Executive Span of Supervision

Supervision 84 272 1 : 3

Executive Non Executive

272 988 1 : 4

3.6                      Activities of Key Functional Departments in SPLAs per the latest organogram SPL had 20 (twenty) functional departments for its operation. The

names of the departments are as follows:

1. Information Technology (IT) Department

2. Medical Services Department (MSD)

3. Product Management Department (PMD)

4. Sales Department

5. Distribution Department

6. International Marketing Department

7. Market Research and Planning Cell

8. Quality Management and Audit Dept.

9. Production Planning and Inventory Cell

10. Engineering Department

11. Production Department

12. Commercial Department

13. Personnel and Administration Department

14. Technical Services Department

15. Human Resource Training and Development Department

16. Quality Control Department

17. Quality Assurance Department

18. AgroVet Department

19. Accounts and Finance Department

20. Accounts (New Venture) Department

Organizational Structure

 

Managing Director

 

Marketing

Services

Officer

 

 

 

 

 

 

 

Product

Group

Manager

 

 

 

 

 

 

 

Senior

Brand

Manager

 

 

 

 

 

 

 

Brand

Manager

 

 

 

 

 

 

 

 

 

 

 

The following departments manage domestic marketing operation:

 

1. Product Management Department (PMD)

2. Sales Department

3. Medical Services Department (MSD)

4. Distribution Department

5. Market Research and Planning Cell

 

The following paragraphs describe the key functions of the above-mentioned Departments:

 

Information Technology (IT) Department

 

The main functions of IT Department are as follows:

 

1. Provide computer and other related accessories supports to all the user

2. Maintenance of server and ensure smooth LAN operation

3. Provide up to date technical and software support to all the sectors of SQUARE

4. Development and maintenance of centralized databases and provide routine and ad hoc reports

for management decision making.

 

Medical Services Department (MSD)

 

The main functions of MSD are as follows:

 

Arranging clinical meeting with the physicians on different products

Provide answers to different queries of the physicians through mail or telephone

Arranging education programs for the rural medical practitioners

Publishing of medical journals

Arranging of special promotional campaign of different products

 

Product Management Department (PMD)

PMD is the core and centralized department for managing the total marketing effort. Basically

PMD performs the all planning, implementation of plans as part of marketing management

functions. The two key functions of PMD are as follows:

1. Introduction of new product into the market

2. Manage the existing portfolio to achieve the marketing objectives.

To this end PMD undertakes all relevant activities including the following:

1. Preparation of Marketing Plan.

2. Designing and development of promotional materials

3. Training of field forces

4. Feasibility study of new products

5. Management of regulatory affairs with Drugs Administration

6. Preparation of printed promotional material (literature/pad/brochure/show card etc.).

7. All relevant coordination works with supplier/factory and procurement department concerning

machinery and raw materials that will be used to manufacture the concerned brands.

Sales Department

1. Pay regular visit to the doctors; show the benefits of new existing products with the help of

promotional tools.

2. Monitor the competitors’ activities.

3. Handles initial product queries from doctors and product complain from the market.

4. Receive sales order from the retailers /drug stores.

5. Coordination among different markets

6. Market rearrangement

7. Handling different problems of field forces

Distribution Department

Ensure smooth distribution of products to all over the country

Collection of payments from the customers

Performs functions as the representative of SPL at the depot level.

Maintenance of vehicles and depots

International Marketing Department

Exploration of new markets all over the world

Operating of export business in the different countries

Provide training to field forces in overseas countries

Provide all types of documents for registration of SPL’s products in overseas countries.

 Market Research and Planning Cell

Performing market survey on the Bangladesh Pharmaceutical Market

Regular prescription share analysis and report generation for SPL market share analysis.

Performing different market research work on different issues

Provide all kinds of support to Field Colleagues in effective planning in the market level.

 

Quality Management and Audit

Ensure the practices of Quality Management System (QMS) at every stage of operations of SPL

in full compliance with ISO 9001.

To monitor the activities to ensure compliance with defined quality policy at every stage of

business.

Develop process and instructions for continuous development of operations to increase

productivity.

 

Production Planning and Inventory Cell (PPIC)

Prepare the monthly production schedule of different products

Maintain the inventory status of different raw materials and packaging materials

 

Technical Services Department (TSD)

1. Provide technical support to QC, QA, Production and other departments with regards to any kind of

technical issues.

2. To procure new Raw Material and production and quality facilities in coordination with Commercial

Dept.

3. Development of formulation of new products

4. Selection of machinery and equipment including spare parts.

5. Coordination and follow-up of the designing and implementation of the Master Plan of the factory.

All matters related to development of factory facilities.

6. Handling various forms of product complaints from market, field forces, and different departments.

7. Recipe development and necessary changes in formulations, product improvement.

 

Current performance of SPL

Chapter

4

 

4.1          Corporate financial highlights 

As on March 31, 2006 the corporate financial position of SQUARE was as follows:

1. Authorized Capital Tk. 1000 Million

2. Issued, Subscribed and Paid up Capital Tk. 436.8Million

3. Reserve/Surplus (Retained Earnings) Tk. 872 Million

4. Share Premium Tk. 800 Million

5. Long Term Loans Tk. 210 Million

6. Number of Shareholders (2006) 13,206

 

 

4.2          Corporate operational results

The following three years financial data proves that SPL is operating through maximizing the

shareholders’ benefits.

(Figures in thousands)          

2003-2004

(12 months)

2004-2005

(12 months)

2005-2006

(12 months)

1 Turnover (Gross) 3451523 4234244 4729743

2 Value Added Tax 450577 563433 663892

3 Turnover (Net) 3000946 3670811 4065851

4 Gross Profit 1081340 1435655 1466282

5 Net Profit before Tax 691636 905736 929604

6 Net Profit after Tax 573677 759448 764885

7 Paid-up Capital 300,000 300,000 300,000

8 Earning per Share 229.47 253.15 254.96

9 Dividend per Share 70.00 75.00 70.00

 

4.3          Output/Capacity utilizationThe actual production of the various categories of products (except inhalers) including chemicals

increased substantially leading to higher capacity utilization as summarized below:

Product

Categories

Units Production (‘000) % age

increase /

(Decrease)

Capital Utilization

2005-

2006

2004-

2005

2005-

2006

2004-

2005

1 Tablets Pcs 1829089 1736561 5% 105% 231%

2 Capsules Pcs 295234 286350 3% 96% 119%

3 Liquids Bottles 21210 16105 32% 118% 153%

4 Injectables Pcs 13325 23075 (42%) 74% 90%

5 ENT

Preparations

Phials 8651 10778 (20%) 192% 207%

6 Opthal

Preparations

Phials 1083 966 12% 181% 116%

7 Dry Syrup Bottles 4048 2634 54% 169% 88%

8 Inhalers Can 298 148 101% 50% -

9 Basic

Chemicals

Kg 219 201 9% 64% 59%

10 Tablets-

AgroVet

Pcs 1262 1697 (26%) 67% 99%

11 Powder-

AgroVet

Gm 34911 15252 129% 189% 127%

The capacity utilization rate in some areas of production decreased due to strategic changes in

favor of increased production of higher value added products in each category resulting in higher

turnover in value. 

4.4          Dhaka ExpansionDespite numerous oddities and complex artifices usually associated with a state-of-art plant, the

management is in the final phase of implementation of the project with the planning, supervisory

and technical support form the consultants e.g. M/s Bovis Lendles and Tanvec of UK and KUPPA

collaboration of Thailand, though the target of commissioning had to be revise / shifted a few

times in the past. It may be appreciated that the project in hand is only of its kind in the region

with USFDA and EU pharmaceutical manufacturing standards requiring highly rigid and

unquestionable quality of materials, workmanship, and performance. The process of

implementation has often suffered from various hazards of communication, transports,

movements and planned accomplishments was not achieved fully due to malfunctioning of ports,

airports, airlines, shipping services, etc. Due to carious reasons as are rampant in the country

since the project was taken in hand. Considering all these factors and the technical complexities

of such a project as well as non-availability of requir5ed man-machine-material in Bangladesh,

the delay in implementation of the project would not be termed unusual and abnormal. It may

also be mentioned that the consultants also had often failed to identify and consider every

possible situation in Bangladesh. In spite of these the unit is scheduled to start functioning by end

2001.

 

During the year 2005-2006, an amount of Tk. 807,016,104 has been invested on various heads

as detailed below:

 

Particulars As on 31-03-05 As on 31-03-06 Increase

1 Land & Land Development 86,725,346 107,550,519 20,825,173

2 Building/Civil Work 318,783,360 812,111,406 493,328,043

3 Imported Plant & Machinery 348,897,963 576,923,068 228,025,105

4 Other Assets 6,315,634 19,954,395 13,638,761

5 Interest during Construction Period 5,577,622 47,501,489 41,923,867

6 Unallocated Expenditures 14,689,009 23,964,161 9,275,152

Total Tk. 780,988,934 1,588,005,038 807,016,104

The remaining implementation work is expected to be now completed by end of 2004 at an

estimated final cost of Tk. 1,830 million and commence production thereafter.

Square Dhaka Unit Project work was started from October 1996, which completed by end of

March 2000. After technical review and in the best interest of the project in order to achieve

quality work as State-of-the-art facility to meet the requirement of the USFDA/MCA Good

Manufacturing Practice the original project completion schedule had to be extended.

The Dhaka Unit New Pharmaceuticals Production Facility at Kaliakoir is going to be one of its

kind in the country to face the challenge of free world market in the beginning of new millennium.

The State-of-Art Facility incorporated certain basic requirement in the area of Purified Water

System. Floor Construction, HVAC System Process Equipment and Validation/ Qualification

Documentation as stipulated by USA, EU and other developed countries.

4.5          Export market

The company’s export drive is being continued with great stress. However, there are number of

problems in exports of medicines from Bangladesh. As a result, the value of exports in Taka

declined by 9.1%. To counter this in future, registration process of products for export purposes

has been initiated in few more countries. The company expects to make a break through in

exports when the Dhaka Unit is commissioned.

(Taka in ‘000) 

Year Turnover (Gross) Exports % age of gross turnover

2005-2006 2,655,952 40,324 1.52%

2004-2005 2,422,785 44,361 1.83%

2003-2004 2,055,418 15,082 0.73%

 

The company has so far been able to enter into the markets of Russia, Pakistan, Sri Lanka,

Myanmar, Nepal, Combodia. It is expected that after the Dhaka Unit goes into production the

company will succeed in entering the markets of developed countries with expanded share of

exports.

 

4.6          Financial results 

The operating financial results of the company for the year under report as compared to the

previous year are as follows:

Figure in thousand : BDT

2005-

06

2004-

05

2003-

04

2002-

03

2001-

02

Turnover (Gross) 7,085,55

3

6,199,13

5

5,482,08

8

5,482,08

8

4,234,24

4

Value Added Tax 995,648 867,088 760,536 663,892 563,433

Turnover (Net) 6,089,90

5

5,332,04

7

4,721,55

2

4,065,85

1

3,670,81

1

Gross Profit2,564,50 2,172,59 1,906,59 1,466,28 1,435,65

3 3 2 2 5

Net Profit before Tax 1,533,04

3

1,513,01

9

1,151,63

6

929,604 905,736

Net Profit after Tax 1,165,86

5

1,255,84

8

970,044 764,885 759,448

Shareholders Equity 6,402,01

5

5,568,79

0

4,590,14

2

3,851,09

8

3,273,71

4

Total Assets9,298,98

7

7,907,93

3

6,021,49

7

5,164,32

0

4,526,11

5

Total Bank Borrowings 2,334,92

5

1,902,33

1

988,611 1,070,16

3

1,098,87

4

Total Current Assets 4,031,68

5

3,242,50

2

2,016,05

6

1,441,55

2

1,452,49

4

Total Current Liabilities 2,260,75

5

1,949,94

9

1,250,67

6

1,247,96

7

1,181,47

3

Current Ratio 1.78 1.66 1.62 1.16 1.23

 

 

 

4.7          Concluding commentsSquare Pharmaceuticals Ltd. has a very good working environment where the employees get

enough opportunity to show their ability and creativeness. Its communication channel is superb.

Informal channel of communication is very active. Many interdepartmental issues are solved in

informal meetings, often over a cup of tea. Introduction of LAN has smoothened the process.

Every member of Square Pharmaceuticals Ltd. feels like he or she is a member of the Square

family. This family feeling is a big asset for this company. Most of the employees are dedicated

and motivated to work. Since good performance is always highlighted and creative ideas

welcomed people are eager to contribute their best.

Square Pharmaceuticals Ltd. believes in honesty in every phase of business. The management

promotes this idea to its workers. The image of the company is also good all over the country.

Customers all over the country recognize Square as a quality company and an honest company.